Latest News

The POSEIDON clinical trial shows that high-sensitivity C-reactive protein levels remain elevated in approximately 2 in 5 patients with CVD, pointing to a gap in residual inflammatory risk management.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

Only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported for BPC-157.

A randomized clinical trial found that both family-based therapy and individual psychoeducational motivational therapy improved symptoms of avoidant/restrictive food intake disorder.

Tregzi is indicated in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival.

As OTC drink-spiking detection products become more widely available, pharmacists can play a critical role in counseling patients on their benefits, limitations, and appropriate response to suspected drink tampering.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

Findings from a multicenter cohort study suggest glucagon-like peptide-1 (GLP-1) receptor agonist therapy may be associated with an elevated risk of sensory disturbances.

The approval adds a 55-mg prefilled syringe for weight-based dosing and makes risankizumab the first IL-23 inhibitor cleared for pediatric patients weighing less than 40 kg.

The blood test offers a promising new approach to identify patients who are at high risk for recurrence and guide precision treatment strategies.

Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.

Oncology Pharmacists Connect 2026 emphasized the pharmacist’s role in translating rapidly evolving evidence into patient-centered, operationally feasible cancer care.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

PCOS becomes PMOS, spotlighting metabolic and endocrine risks.

Be confident that you have researched all avenues and feel secure in making your recommendations.

Veligrotug-vvze is the first FDA-approved thyroid eye disease treatment with data in both active and chronic disease.

A combination regimen of azacitidine, venetoclax, and gilteritinib shows encouraging benefits in patients with newly diagnosed FLT3-mutated AML who were ineligible for intensive chemotherapy.

Biosimilars are equally safe and cut costs. Pharmacists can ease patient fears at the counter.

Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, after reduced recurrence risk in lidERA trial.

In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.